addition, in a meta-analysis of 64 studies, there was an association between higher triglyceride levels and relative risk (RR) of stroke (adjusted RR, 1.05; 95% CI, 1.03 to 1.07) for each 10-mg/dL increase in baseline triglycerides; fasting and nonfasting status were not specified. 25 Studies have also shown that triglycerides levels are inversely associated with hemorrhagic stroke risk (Table 2) . 16, 17 
T he relationship between lipids and stroke is complex. In most epidemiological cohorts, there is a direct relationship between cholesterol levels and ischemic stroke. The relationship of lipids to ischemic stroke, however, varies by stroke subtype, with associations strongest for atherosclerotic subtypes. Conversely, there is an increased risk of intracerebral hemorrhage (ICH) at low cholesterol levels, and there is evidence that small vessel disease may share a similar profile of inverse association with lipid levels. The associations also depend on the specific lipid component considered, with the data strongest for total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C). Given the availability of increasingly potent lipid-lowering agents, understanding the relationship between dyslipidemia and stroke may improve primary and secondary stroke prevention strategies.
Here, we review the literature on the relationship between dyslipidemia and stroke, with a focus on lipid screening recommendations and evidence-based approaches to management.
Lipid Parameters and Stroke Risk Total and LDL-C
In most, but not all, observational studies, there is an association between higher total and LDL-C levels and increased ischemic stroke risk (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In addition, most observational studies also found an association between lower TC and LDL-C levels and increased risk of hemorrhagic stroke (Table 2) . 2, [13] [14] [15] [16] [17] A recent metaanalysis of 23 studies showed an inverse dose-response association between TC and hemorrhagic stroke (odds ratio [OR] , 0.85 per 1 mmol/L increment; 95% confidence interval [95% CI], 0.80-0.91). 18 The mechanism of this association remains unclear. Some studies, however, have shown low serum LDL-C levels in patients with liver disease 19 and hematologic malignancies 20 who are at a higher risk of ICH. This hypothesis can be tested in large population-based cohorts.
Overall, epidemiological studies suggest competing stroke risk related to TC levels in the general population; high TC is associated with higher risk of ischemic stroke, whereas lower levels are associated with higher risk of brain hemorrhage.
Present data do not permit specification of an acceptable cholesterol threshold with regard to these competing risks in either men or women, however.
High-Density Lipoprotein-Cholesterol and HighDensity Lipoprotein Subfractions
In some studies, there is an inverse relationship between high-density lipoprotein-cholesterol (HDL-C) and stroke (Table 1) . 5, 7, 8 A systematic review of 10 prospective studies found a decreased risk of ischemic stroke ranging from 11% to 15% for each 10-mg/dL increase in HDL-C. 21 Because studies of the association between HDL-C and stroke yielded mixed results, and recent evidence showed no benefit of HDL-increasing medications on ischemic stroke risk, 22 some suggest that the relationship between HDL and cerebrovascular disease is a function of HDL-C subfractions rather than of total HDL-C. HDL has 2 main subfractions: larger and less dense HDL-C (HDL2) and smaller and denser HDL-C (HDL3). These subfractions differ in their biological activity, biochemical properties, and vascular metabolism. HDL3, more so than HDL2, seems to inhibit LDL oxidation and protect against atherosclerosis by its action on the vascular endothelium.
In the Northern Manhattan Study (NOMAS), HDL subfractions had differential effects on the risk of carotid disease; there was a direct relationship between HDL2 and plaque thickness and an inverse relationship between HDL3 and plaque area. 23 In a nested prospective case-control analysis from the Circulatory Risk in Community Study, small-and medium-sized HDL particles were associated with reduced risk of ischemic stroke, in particular, lacunar infarcts, and ICH, whereas HDL2 was not associated with stroke risk. 24 More studies are needed to better understand the relationship of HDL subfractions and stroke risk.
Triglycerides
Epidemiological studies evaluating triglycerides and ischemic stroke also show mixed results, partly because of differential use of both fasting and nonfasting levels (Table 1) . 5, 11, 12 In Lp(a) levels ≥30 mg/dL at baseline were associated with an increased risk of ischemic stroke. This association was more pronounced among men and blacks. 30 The effects of Lp(a), therefore, may depend on race-ethnic and other demographic factors, but more research is needed.
Lipids and Ischemic Stroke Subtypes
Some of the discrepant results among observational studies of lipids and stroke risk may be explained by the differential association with ischemic stroke subtypes: there is a stronger association between lipids and strokes because of large artery atherosclerosis. In a case-control study, the association between cholesterol and ischemic stroke risk was strongest for large artery atherosclerosis (OR, 3.2). 31 The association between dyslipidemia and large artery atherosclerotic stroke subtype was also shown in other studies. 32, 33 On the contrary, not all studies showed an association between dyslipidemia and lacunar stroke. In case-control studies, there have been associations between levels of TC 31 and LDL 34 with lacunar stroke. Other studies, however, did not show an association between dyslipidemia and lacunar stroke. 32, 33 Thus, the relationship between dyslipidemia and lacunar stroke is complex and likely influenced by genetic and demographic factors in different patient populations, as well as differences in defining stroke subtypes.
Although dyslipidemia is a risk factor for coronary heart disease, most studies showed no association between dyslipidemia and embolic stroke.
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Lipids, White Matter Disease, and Cerebral Microbleeds
White matter hyperintensity (WMH), or leukoariosis, has been associated with stroke risk factors including age, hypertension, and smoking. 35 Because WMH, cerebral microbleeds, and deep ICHs are often considered different manifestations of small vessel disease, the relationship between lipids and each of WMH and cerebral microbleeds may help explain the relationship of lipids to small vessel disease. In fact, studies have shown an inverse relationship between dyslipidemia and both WMH 36, 37 and cerebral microbleeds, 38 providing evidence that lower lipid levels may impair small vessel structure or function.
Taken together, the above data provide some evidence of the inverse association between small vessel disease (WMH and CMBs) and hyperlipidemia. This may relate to the role that cholesterol plays in the architecture and integrity of the normal endothelium of small vessels; thus, low lipid levels may interfere with the integrity of the endothelium or impair endothelial reparative processes, causing leakage or obstruction of the small vessels. The exact mechanism remains uncertain, and more studies are needed to better characterize the mechanism of this association.
Screening for Lipid Levels After Stroke
In patients with ischemic stroke, a serum lipid profile including TC, LDL, HDL, and triglycerides should be performed. 39 On the contrary, given the scarcity of evidence, routine testing for other lipid components such as Lp(a) and HDL subfractions is not recommended.
The LDL-C usually reported in the lipid profile is generally calculated using the Friedewald formula 40 :
LDL -C = TC (very low -density lipoprotein -cholesterol
This formula is more accurate in the fasting state, because in nonfasting patients, postprandial chylomicrons may contribute to TC levels and make the measurement less accurate. In addition, this method is inaccurate when the triglyceride level is ≥400 mg/dL and has a higher error margin when the LDL is ≤70 mg/dL. 41 Direct assays have been developed to measure cholesterol level. Although direct assays are much more expensive than using the Friedwald formula, they may The timing of lipid measurements after stroke may be less important than after myocardial infarction. There is evidence that lipid levels after stroke do not decline as markedly as after myocardial infarction. 42 In a meta-analysis of 68 studies that included >300 000 patients, moreover, the association between lipid components and ischemic stroke persisted even when measured in nonfasting patients. 43 As noted above, associations with triglycerides were even more prominent in the nonfasting state. Therefore, although the lipid profile is preferably measured fasting, it can probably be tested even in the nonfasting state, 44 and at any time after the stroke, and should include at least TC, LDL, and HDL-C levels.
Lipid-Lowering Therapy and Stroke
Statin Therapy in Primary Stroke Prevention
In addition to their cardiovascular benefits, statins have demonstrated efficacy in reducing stroke risk. In primary stroke prevention trials, several statins have been associated with reductions in risk of stroke ranging from 11% to 40%. The Heart Protection Study (HPS) randomized >20 000 patients aged 40 to 80 years with high risk of vascular disease to simvastatin 40 mg daily versus placebo. There was a 25% reduction in stroke risk without an increase in the risk of hemorrhagic stroke. 45 More aggressive treatment was associated with a further reduction in risk. In the Treating to New Targets (TNT) study, compared with atorvastatin 10 mg daily, atorvastatin 80 mg daily was associated with a 25% reduction in stroke risk that correlated with reductions in LDL. Furthermore, metaanalyses of lipid therapy and stroke showed that with each 1-mmol/L reduction in LDL-C, there was ≈20% RR reduction in ischemic stroke. 46, 47 
Statin Therapy in Secondary Stroke Prevention
A post hoc analysis of the HPS study showed that in the 3280 patients with a history of cerebrovascular disease without coronary disease, simvastatin treatment was associated with a 5% reduction in the risk of major cardiovascular events or death when compared with placebo. 45 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, however, provides the most direct evidence on the role of statins in secondary stroke prevention. SPARCL randomized 4731 patients with stroke or transient ischemic attack and baseline LDL 100 to 190 mg/dL to atorvastatin 80 mg versus placebo beginning 1 to 6 months after their event. Over a median follow-up of 5 years, atorvastatin was associated with an ≈2% absolute reduction in recurrent total stroke risk (13.1% versus 11.2%), with a RR reduction of 16%. 48 The benefits of statins on risk reduction were similar across subtypes of the index stroke subtype as well, implying that all patients with ischemic stroke, regardless of subtype, should receive statin therapy. Current professional society guidelines, however, reflect a slightly more conservative approach, recommending statin therapy with intensive lipid-lowering effects (ie, reduces LDL by >50%) for patients with ischemic stroke or transient ischemic attack presumed to be of atherosclerotic origin. 39 The guidelines do recommend treatment for patients with stroke with LDL levels <100 mg/dL, however, which is even lower than the criteria for inclusion in SPARCL, reflecting both the recognition that patients with stroke have a similar high risk of future cardiovascular events because patients with other forms of atherosclerotic disease and that use of statin therapy should be based on overall risk rather than only on lipid levels. 49 SPARCL is the first clinical trial to prove the benefit of high-dose statin therapy in secondary stroke prevention, but the effect was modest with a number needed to treat 50 >5 years. SPARCL had several limitations, however. For instance, patients were randomized at 1 to 6 months after stroke, the period where the risk of stroke recurrence falls, especially in patients with large artery atherosclerosis in whom statins may provide the most stroke prevention benefit. Ongoing trials are addressing the role of statin therapy given immediately after stroke, not only to reduce lipid levels and prevent recurrent stroke but also to ameliorate cerebral injury related to the stroke itself. For example, the Neuroprotection with Statin Therapy for Acute Recovery (NeuSTART) trial is a phase II trial randomizing patients with acute ischemic stroke to lovastatin 640 mg daily for 3 days versus placebo to determine the safety and efficacy of lovastatin in reducing infarct size and promoting stroke recovery, which may be a function of the pleiotropic effects of statins. 50 In addition, SPARCL did not establish a target LDL.
Statins Therapy Beyond Lipid Control
Investigators suggest that a beneficial pleiotropic effect of statins could be through mechanisms different than action on cholesterol metabolism in the liver. These other potential mechanisms include inhibition of the inflammatory cascade, antioxidant effects, upregulation of nitric oxide synthase with consequent increase in cerebral blood flow, plaque stabilization, and modulating coagulation and platelet function. These mechanisms not only have stroke prevention implications but also contribute to improved functional outcome in acute ischemic stroke.
Other Lipid-Lowering Drugs in Stroke Prevention
The benefit of nonstatin lipid-lowering agents for primary or secondary stroke prevention is not as well established. Although niacin increases HDL levels, its benefit in reducing the risk of cerebrovascular events remains uncertain. A metaanalysis of 11 studies (n=9959 subjects) showed no association between the use of niacin and the risk of stroke (OR, 0.88; 95% CI, 0.50 to 1.54). 51 Fibric acid derivatives can also be used to lower triglycerides and increase HDL-C levels, but their efficacy in reducing incident stroke is uncertain. The Veterans Affairs-HDL Intervention Trial (VA-HIT) among men with coronary artery disease and low HDL-C, benzofibrate provided a 31% reduction in stroke risk (P=0.036). 52 A recent meta-analysis, however, included 18 trials, and >45 000 patients provided no evidence that fibrates reduce stroke risk (RR reduction, −3%; 95% CI, −16 to 9). 53 Ezetimibe inhibits the intestinal absorption of cholesterol, reducing TC levels. The recently published Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) showed that the addition of ezetimibe 10 mg daily to simvastatin 40 mg daily resulted in a
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A meta-analysis that included 78 trials of lipid-lowering agents showed no significant stroke risk reduction of nonstatin lipid-lowering interventions including fibrates, other treatments, and diet (OR, 0.92; 95% CI, 0.69 to 1.23).
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Novel Lipid-Lowering Drugs Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a hepatic protease that degrades hepatic LDL receptors leading to increased serum LDL-C levels. Monoclonal antibody inhibitors of PCSK9 are novel parenterally administered lipid-lowering agents that have been shown to reduce LDL by 60% to 70% when added to statin therapy. 56 A meta-analysis of 24 randomized trials including >10 000 subjects using PCSK9 inhibitors found a significant reduction in all-cause mortality (OR, 0.45; 95% CI, 0.23 to 0.86) and myocardial infarction (OR, 0.49; 95% CI, 0.26 to 0.93). 57 In addition, a phase III study showed that alirocumab, one of the PCSK9 inhibitors, was associated with a 62% reduction in LDL, and this translated into a 48% decrease risk of major cardiovascular events. However, there was no difference in stroke risk between the treatment and the control groups (0.6% versus 0.3%; P=0.35) although the stroke risk was low. Some adverse events, including myalgias, injection site reactions, ophthalmologic events, and neurocognitive events (including memory impairment and confusional state), occurred more often in patients receiving alirocumab. 58 The mechanisms of cognitive changes are uncertain, but could reflect changes in white matter integrity in the setting of extremely low LDL levels. Evolocumab is another monoclonal antibody that inhibits PCSK9 that has been shown in a randomized open trial (n=4465 patients) to be superior to standard of care (70% of which included statin therapy) in reducing cardiovascular events over a median follow-up of 11.1 months (hazard ratio 0.47; 95% CI, 0.28 to 0.78) with the similar overall serious adverse event profile (7.5% in each group). More patients on evolocumab had neurocognitive deficits (0.9 versus 0.3%), however. 59 These monoclonal antibodies are currently approved by the Food and Drug Administration, but their use may be challenged by the need for injections. Randomized trials are needed to prove the safety and efficacy of alirocumab and other PCSK9 inhibitors as an add-on treatment to statins in patients with elevated LDL for primary and secondary stroke preventions, particularly in light of the potential for neurocognitive effects.
Statins and ICH
Although evidence suggests an inverse relationship between lipids and hemorrhagic stroke, the association between statin use and ICH remains unclear. The HPS study was the first clinical trial to show a nonsignificant increase in the risk of ICH with simvastatin versus placebo (1.3% versus 0.7%). 45 In SPARCL, patients on atorvastatin were more likely to have ICH than those on placebo (2.3% versus 1.4%; P=0.01). 48 A recent meta-analysis including 31 clinical trials, however, showed no increase in risk of ICH with statin use (OR, 1.08; 95% CI, 0.88 to 1.32). 60 Any potential increase in risk of ICH is likely to be low, therefore.
Guidelines on Lipid Management
The most recent American Heart Association/American Stroke Association guidelines recommend high-intensity statin therapy for patients with ischemic stroke presumed to be related to atherosclerosis, regardless of LDL level. High-intensity statin therapy is defined as therapy sufficient to lower the LDL-C by at least 50%; no specific target values are provided any longer. The guidelines further recommend that use of statin therapy in patients with nonatherosclerotic mechanisms should be based on their overall cardiovascular risk and comorbid conditions. 39 This is also based on the American College of Cardiology/ American Heart Association guidelines that move away from reliance on LDL levels to determine the intensity of statin therapy. 44 According to these guidelines, statin therapy is recommended to patients with (1) clinical atherosclerotic cardiovascular disease (atherosclerotic stroke or transient ischemic attack and coronary artery disease); (2) LDL-C ≥190 mg/dL; (3) age 40 to 75 years, diabetes mellitus, and LDL-C 70 to 189 mg/dL; (4) LDL-C 70 to 189 mg/dL, no diabetes mellitus, and estimated 10-year atherosclerotic cardiovascular disease risk of ≥7.5% based on the new pooled cohort equations. Highintensity statin therapy is recommended for those <75 years and at low risk of statin complications, with atherosclerotic cardiovascular disease, LDL-C ≥190 mg/dL, or diabetes mellitus and a 10-year risk of atherosclerotic cardiovascular disease of ≥7.5%. Moderate intensity statin therapy (ie, a lowering of LDL-C of 30%-50%) is recommended for other groups.
Conclusions
Lipids have a complex relationship with cerebrovascular disease. There is a direct relationship between cholesterol levels and ischemic stroke, and particularly atherosclerotic disease, and the associations are strongest for TC and LDL. There is an increased risk of ICH at low cholesterol levels, and there is evidence that low lipid levels also increase the risk of small vessel disease. Statins reduce the risk of recurrent stroke after ischemic stroke, but the role of adding newer lipid-lowering agents remains to be determined.
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addition, in a meta-analysis of 64 studies, there was an association between higher triglyceride levels and relative risk (RR) of stroke (adjusted RR, 1.05; 95% CI, 1.03 to 1.07) for each 10-mg/dL increase in baseline triglycerides; fasting and nonfasting status were not specified. 25 Studies have also shown that triglycerides levels are inversely associated with hemorrhagic stroke risk (Table 2) . 16, 17 
Lipoprotein(a)
Lipoprotein(a) (Lp(a)) has been identified as an emerging risk factor for cardiovascular disease. Plasma levels of Lp(a) are influenced by genetic factors, with substantial differences across ethnic groups, with levels being highest among blacks. 26 Studies on the relationship between Lp(a) and risk of ischemic stroke yielded mixed results. In a nested casecontrol study of 15 000 healthy predominantly white middleaged physicians, Lp(a) levels were not associated with stroke risk. 27 In a European cohort, plasma Lp(a) levels also were not associated with ischemic stroke. 28 In Atherosclerosis Risk in Communities, Lp(a) levels ≥30 mg/mL were associated with increased risk of ischemic stroke in black and white women, but not in white men. 29 In a NOMAS case-control study, (Table 2) . 16, 17 지질단백질 ( Lp(a) levels ≥30 mg/dL at baseline were associated with an increased risk of ischemic stroke. This association was more pronounced among men and blacks. 30 The effects of Lp(a), each of WMH and cerebral microbleeds may help explain the relationship of lipids to small vessel disease. In fact, studies have shown an inverse relationship between dyslipidemia and and receives royalties from UpToDate for chapters related to cryptogenic stroke and hemicraniectomy. Dr Elkind receives funding from the NIH.
